We have previously demonstrated that MIF, a synthetic PR antagonist that has been safely used as an abortifacient and an emergency contraceptive for decades 21, has an anti-tumor activity in basal TNBC cells through inhibiting KLF5 expression at relatively high doses (10-20 μM) 13. This evidence concerns the gene MIF and neoplasm.